FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Review
September 26 2016 - 2:03AM
Dow Jones News
By Inti Landauro
PARIS--The U.S. Food and Drug Administration is to undertake a
priority review of a treatment for atopic dermatitis, a chronic
inflammatory skin disease, according to pharmaceutical firms Sanofi
SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) which make
the drug.
The two companies had said in June that a series of trials
showed the treatment, known as dupilumab, combined with topical
corticosteroids significantly improved the condition of a group of
patients suffering from atopic dermatitis.
Back in 2014, the FDA had granted "breakthrough therapy"
designation to dupilumab.
Large pharmaceutical companies like Sanofi are rushing to get
new drugs to market to offset falling revenues from top-selling
drugs whose patents recently expired.
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
September 26, 2016 01:48 ET (05:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
